Literature DB >> 10662392

Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

R Baltussen1, R Leidl, A Ament.   

Abstract

This paper identifies the information that economic evaluation should provide to adequately inform policy-makers. First, policy-makers need cost-effectiveness information that is both internally and externally valid. The latter aspect is often ignored and refers to the relevance of the results of economic trials to the specific decision-making context of the policy-maker. Second, policy-makers, like purchasers of care, may want assessments of the overall budget and health impacts of adopting an intervention in a disease or treatment area. This requires more of an aggregate analysis than the current approaches to economic evaluation (which are typically individual-orientated). There are 3 main conceptual approaches to economic evaluation: the use of randomised controlled trials (RCTs), observational studies and modelling. The RCT can be considered as the gold standard in economic evaluation because of its high internal validity, but results should be interpreted with caution because of its low external validity. There a number of options to enhance external validity; of these, additional modelling and observational data seem to be the most promising. To address issues at the system level, disease modelling or public health modelling is suggested. A 3-step approach, comprising successive assessment of internal validity, external validity (real world relevance) and net impact at the system level, can enhance the informative value of economic analyses. For example, this approach has been used to assess the informative value to decision-makers of an RCT in benign prostatic hyperplasia. The analysis emphasised the feasibility and importance of additional modelling beyond the results from an RCT-based economic analysis and provided important information of relevance for policy-making. Because of the need to increase the real world relevance of pharmacoeconomic analyses, there is potentially a large role for modelling in economic evaluation; however, in order to enhance its credibility, more attention should be paid to validity aspects.

Entities:  

Mesh:

Year:  1999        PMID: 10662392     DOI: 10.2165/00019053-199916050-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

1.  Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?

Authors:  M Drummond
Journal:  Health Econ       Date:  1992-07       Impact factor: 3.046

2.  Sleeping giant.

Authors: 
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

3.  The learning curve and the cost of heart transplantation.

Authors:  J R Woods; R M Saywell; A W Nyhuis; S J Jay; R G Lohrman; H G Halbrook
Journal:  Health Serv Res       Date:  1992-06       Impact factor: 3.402

4.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

5.  A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.

Authors:  S Morris
Journal:  Health Econ       Date:  1997 Nov-Dec       Impact factor: 3.046

6.  Problems of using modelling in the economic evaluation of health care.

Authors:  T A Sheldon
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

7.  Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group.

Authors:  B J O'Brien; D Heyland; W S Richardson; M Levine; M F Drummond
Journal:  JAMA       Date:  1997-06-11       Impact factor: 56.272

8.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

9.  Some factors to consider when using the results of economic evaluation studies at the population level.

Authors:  R M Leidl
Journal:  Int J Technol Assess Health Care       Date:  1994       Impact factor: 2.188

Review 10.  Economic impact of the AIDS epidemic in the European Community: towards multinational scenarios on hospital care and costs.

Authors:  M J Postma; R Leidl; A M Downs; J Rovira; K Tolley; M Gyldmark; J C Jager
Journal:  AIDS       Date:  1993-04       Impact factor: 4.177

View more
  17 in total

Review 1.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

2.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Conceptual framework for standard economic evaluation of physical activity programs in primary prevention.

Authors:  Silke B Wolfenstetter
Journal:  Prev Sci       Date:  2011-12

5.  Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.

Authors:  Philippe Fagnoni; Samuel Limat; Loïc Chaigneau; Emmanuel Guardiola; Stéphanie Briaud; Bernard Schmitt; Yacine Merrouche; Xavier Pivot; Marie-Christine Woronoff-Lemsi
Journal:  Support Care Cancer       Date:  2006-06-27       Impact factor: 3.603

Review 6.  Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

Authors:  Michael Schlander
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

7.  From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.

Authors:  Samuel Limat; Marie-Christine Woronoff-Lemsi; Céline Menat; Anne Madroszyk-Flandin; Yacine Merrouche
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.

Authors:  Madeline Betancourt; Peggy S McKinnon; R Michael Massanari; Salmaan Kanji; David Bach; John W Devlin
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.

Authors:  Amr A Saad; Darren M Ashcroft; Kath D Watson; Deborah P M Symmons; Peter R Noyce; Kimme L Hyrich
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.